SOURCE: Agennix AG

Agennix AG

March 04, 2011 03:49 ET

Agennix AG Announces Changes to Management Board and Supervisory Board

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX--(Marketwire - March 4, 2011) - Agennix AG (FRANKFURT: AGX) (XETRA: AGX) today announced changes to its Management Board and Supervisory Board.

Friedrich von Bohlen und Halbach's term as interim Chief Executive Officer expired on February 28, 2011. Effective March 1, 2011, as resolved by the Supervisory Board, the Company is being led by a two-person Management Board comprised of Dr. Torsten Hombeck, Chief Financial Officer, and Dr. Rajesh Malik, Chief Medical Officer. Dr. Hombeck also has been appointed to serve as spokesperson of the Management Board.

Dr. Hombeck said, "On behalf of all of us at Agennix, I would like to warmly thank Dr. von Bohlen for serving as CEO during the formation and integration of the Company. His leadership and experience during this critical time have been very helpful."

The Company also reported changes to its Supervisory Board. Dr. Juergen Drews has informed the Company that he is resigning from the Board. As previously provided for at the time of the closing of the merger of GPC Biotech into Agennix AG in November 2009, Dr. von Bohlen will be filling this seat.

Dr. von Bohlen said: "I am pleased to know that the leadership of Agennix is in the capable hands of Dr. Hombeck and Dr. Malik, who have demonstrated their strong management skills over the past year in advancing the business. I look forward to continuing to serve the Company as a member of the Supervisory Board."

The Company also reported that, effective February 14, 2011, Alan Feinsilver filled the Supervisory Board seat opened by the resignation of Dr. Robert van Leen, which was announced in November 2010. Mr. Feinsilver had previously been named as a replacement member for Dr. van Leen at the time of the closing of the merger. Mr. Feinsilver is the owner and President of The Overbrook Company, a private investment company. He is also the Managing Director of Centerline Manufacturing Ltd., a private company which produces specialty parts for the energy industry. He has served on the Board of Directors of several U.S. firms, including as Chairman of the Audit Committee for two publicly listed companies. Mr. Feinsilver is a Certified Public Accountant and an attorney. He holds a Bachelors degree in Business Administration from the University of Texas and a Juris doctor degree from the University of Texas School of Law. 

"I would like to sincerely thank Dr. Drews and Dr. van Leen for their service and greatly appreciate their counsel," said Dr. Christof Hettich, Chairman of the Supervisory Board. "I am very pleased to welcome Mr. Feinsilver, as well as my colleague, Dr. von Bohlen, to the Board. Mr. Feinsilver has extensive business experience in both public and private firms, including financial expertise that will be invaluable to the Company and Board."

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Agennix™ is a trademark of the Agennix group.

Contact Information

  • For further information, please contact:

    Barbara Muller
    Manager, Investor Relations & Corporate Communications
    Phone: +49 (0)89 8565 2693

    In the U.S.:
    Laurie Doyle
    Senior Director, Investor Relations & Corporate Communications
    Phone: +1 609 524 5884

    Additional media contact for Europe:
    MC Services AG
    Raimund Gabriel
    Phone: +49 (0) 89 210 228 0

    Additional investor contact for Europe:
    Trout International LLC
    Lauren Williams
    Vice President
    Phone: +44 207 936 9325